Lv22
170 积分 2024-09-29 加入
Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study
41分钟前
已完结
Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial
1个月前
已完结
Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trial
1个月前
已完结
Clinical pharmacology strategies to accelerate the development of polatuzumab vedotin and summary of key findings
8个月前
已完结
EXPRESS:The efficacy and safety of brentuximab vedotin for peripheral T-cell lymphoma: A systemic review and meta-analysis
8个月前
已完结
Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced-Stage Classical Hodgkin Lymphoma
8个月前
已完结
Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced-Stage Classical Hodgkin Lymphoma
8个月前
已关闭
Brentuximab vedotin and nivolumab for cHL
8个月前
已关闭
Brentuximab vedotin and nivolumab for cHL
8个月前
已关闭
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
8个月前
已完结
皖公网安备34019202002308
